In a 60-year-old man with symptomatic hypogonadism and a history of mood disorders, is it appropriate to target a serum total testosterone level of approximately 850 ng/dL with testosterone replacement therapy?

Targeting Supraphysiologic Testosterone Levels (850 ng/dL) in a 60-Year-Old Man with Mood Disorders

Targeting a testosterone level of 850 ng/dL is not appropriate and contradicts evidence-based guidelines; the recommended target is mid-normal range (450–600 ng/dL), and testosterone therapy provides minimal to no benefit for mood disorders even when hypogonadism is confirmed. 1, 2

Why 850 ng/dL Is Not the Correct Target

• Guideline-recommended target range is 450–600 ng/dL (mid-normal), not supraphysiologic levels. 1, 2
• The American Urological Association explicitly recommends targeting the middle tertile of the normal reference range, which corresponds to approximately 450–600 ng/dL. 2
• Treatment programs should use minimal dosing necessary to drive testosterone levels to the normal physiologic range of 450–600 ng/dL, not higher. 2
• Supraphysiologic peaks (which occur 2–5 days after injectable testosterone) are associated with increased risk of erythrocytosis—approximately 44% of men on injectable testosterone develop hematocrit >52%. 1

Testosterone Therapy Does Not Meaningfully Improve Mood Disorders

• Testosterone therapy produces little to no clinically meaningful effect on depressive symptoms, energy, or mood even in men with confirmed biochemical hypogonadism. 1, 3
• In the large TRAVERSE trial (5,204 men), testosterone was associated with only "modest" improvements in mood and energy, with effect sizes too small to be clinically significant. 3
• The standardized mean difference for depressive symptoms is approximately −0.19, classified as "less-than-small" improvement. 1
• Mood disorders should not be the primary indication for testosterone therapy; the only symptoms with proven benefit are diminished libido and erectile dysfunction (standardized mean difference 0.35). 1, 2

Diagnostic Requirements Before Any Testosterone Therapy

• Two separate fasting morning testosterone measurements (8–10 AM) both <300 ng/dL are required to confirm biochemical hypogonadism. 1, 4
• Measure LH and FSH to distinguish primary from secondary hypogonadism—this distinction is critical for treatment selection and fertility counseling. 1, 4
• Qualifying symptoms must include diminished libido or erectile dysfunction; mood symptoms alone do not justify therapy. 1

Correct Treatment Algorithm for This Patient

Step 1: Confirm Diagnosis

• Obtain two morning total testosterone measurements (8–10 AM); both must be <300 ng/dL. 1
• If confirmed low, measure LH, FSH, and prolactin to classify hypogonadism type. 1
• Assess for sexual symptoms (diminished libido, erectile dysfunction)—these are the only symptoms with proven testosterone responsiveness. 1

Step 2: Address Mood Disorder Separately

• Treat the mood disorder with evidence-based psychiatric interventions (SSRIs, psychotherapy) rather than relying on testosterone. 5
• Some studies suggest men on SSRIs may experience additional modest benefit when testosterone is added, but this is not first-line treatment for depression. 5
• The patient should understand that testosterone will not meaningfully improve mood, energy, or cognition. 1, 3

Step 3: If Testosterone Therapy Is Indicated (Based on Sexual Symptoms)

• Target mid-normal testosterone levels of 450–600 ng/dL, not 850 ng/dL. 1, 2
• First-line formulation: transdermal testosterone gel 1.62% (~40 mg daily) due to stable serum levels and lower erythrocytosis risk (15% vs. 44% with injectables). 1
• Alternative: intramuscular testosterone cypionate/enanthate 100–200 mg every 2 weeks, but this carries higher erythrocytosis risk. 1

Step 4: Monitoring Protocol

• At 2–3 months: measure testosterone (midway between injections for injectables, targeting 500–600 ng/dL), hematocrit (withhold if >54%), and PSA (if age >40). 1, 2
• Every 3–6 months during year 1, then annually: repeat testosterone, hematocrit, PSA, and digital rectal exam. 1
• Discontinue at 12 months if no improvement in sexual function, as this is the only domain with proven benefit. 1

Critical Safety Concerns with Supraphysiologic Dosing

• Erythrocytosis risk increases dramatically with higher testosterone levels; hematocrit >54% is an absolute contraindication to continuing therapy. 1
• Elevated hematocrit increases blood viscosity and can exacerbate cardiovascular, cerebrovascular, and peripheral vascular disease—particularly dangerous in a 60-year-old. 1
• Cardiovascular risk: While the TRAVERSE trial showed no increased major adverse cardiac events with transdermal testosterone at physiologic doses, supraphysiologic dosing has not been studied and may carry unknown risks. 1

Common Pitfalls to Avoid

• Do not target supraphysiologic levels (850 ng/dL); this exceeds guideline recommendations and increases adverse event risk without additional benefit. 1, 2
• Do not prescribe testosterone primarily for mood symptoms; the evidence shows minimal to no benefit for depression, energy, or cognition. 1, 3
• Do not diagnose hypogonadism on a single measurement or symptoms alone; two morning values <300 ng/dL plus sexual symptoms are required. 1
• Do not omit LH/FSH testing after confirming low testosterone; this distinction guides therapy and fertility counseling. 1

Expected Realistic Outcomes

• Small improvement in sexual function and libido (standardized mean difference 0.35) if hypogonadism is confirmed and sexual symptoms are present. 1
• Minimal to no improvement in mood, energy, physical function, or cognition even with confirmed hypogonadism. 1, 3
• Modest metabolic benefits (improved insulin resistance, triglycerides, HDL cholesterol) may occur. 1

In summary: The correct target is 450–600 ng/dL, not 850 ng/dL, and testosterone should only be prescribed if biochemical hypogonadism is confirmed with sexual symptoms present—not for mood disorders, which show minimal response to testosterone therapy. 1, 2, 3